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Abstract
Background: Shorter periods of hospitalisation and increasing warfarin use have placed stress on community-
based healthcare services to care for patients taking warfarin after hospital discharge, a high-risk period for these
patients. A previous randomised controlled trial demonstrated that a post-discharge service of 4 home visits and
point-of-care (POC) International Normalised Ratio (INR) testing by a trained pharmacist improved patients’
outcomes. The current study aims to modify this previously trialled service model to implement and then evaluate
a sustainable program to enable the smooth transition of patients taking warfarin from the hospital to community
setting.
Methods/Design: The service will be trialled in 8 sites across 3 Australian states using a prospective, controlled
cohort study design. Patients discharged from hospital taking warfarin will receive 2 or 3 home visits by a trained
‘home medicines review (HMR)-accredited’ pharmacist in their 8 to 10 days after hospital discharge. Visits will
involve a HMR, comprehensive warfarin education, and POC INR monitoring in collaboration with patients’ general
practitioners (GPs) and community pharmacists. Patient outcomes will be compared to those in a control, or ‘usual
care’, group. The primary outcome measure will be the proportion of patients experiencing a major bleeding event
in the 90 days after discharge. Secondary outcome measures will include combined major bleeding and
thromboembolic events, death, cessation of warfarin therapy, INR control at 8 days post-discharge and unplanned
hospital readmissions from any cause. Stakeholder satisfaction will be assessed using structured postal
questionnaire mailed to patients, GPs, community pharmacists and accredited pharmacists at the completion of
their study involvement.
Discussion: This study design incorporates several aspects of prior interventions that have been demonstrated to
improve warfarin management, including POC INR testing, warfarin education and home visits by trained
pharmacists. It faces several potential challenges, including the tight timeframe for patient follow-up in the post-
discharge period. Its strengths lie in a strong multidisciplinary team and the utilisation of existing healthcare
frameworks. It is hoped that this study will provide the evidence to support the national roll-out of the program as
a new Australian professional community pharmacy service.
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Warfarin has been in widespread use since the 1950s
and is currently the most commonly prescribed vitamin
K antagonist worldwide [1]. The use of warfarin in Aus-
tralia is now increasing at approximately 8-10% per year
[2,3], largely because of its proven benefits in preventing
stroke in patients with atrial fibrillation (AF) and the
increasing prevalence of this condition [1,4-7].
Complications of warfarin therapy
Warfarin is recognised as a high-risk drug [4,8-14]; it is
1 of the top 10 agents most frequently associated with
adverse drug events [15]. A number of studies have
reported that the risk of warfarin-related bleeding is
highest early in the course of therapy [16-22], with the
risk for major bleeding during the first month of therapy
approximately 10 times the risk after the first year
[16-18,23].
Traditionally, anticoagulant therapy in Australia is
managed in the community by general practitioners
(GPs) and pathology providers. The combination of
shorter periods of hospitalisation and increasing usage
of warfarin has placed stress on these community-based
health services to care for anticoagulated patients after
discharge from hospital [24]. There is often poor dis-
charge planning [25], insufficient communication
between the hospital and GPs at hospital discharge, and
GPs may extend the interval of INR monitoring too
early and/or increase warfarin dosages too quickly in
newly initiated patients [26].
Hospitalisation has been demonstrated to be an inde-
pendent cause of reduced anticoagulant control [27].
Patients require more frequent International Normalised
Ratio (INR) monitoring in the post-discharge period due
to INR fluctuations resulting from their recovery from
illness and alterations in medication regimens. Commu-
nication difficulties and the potential for misinterpreta-
tion of information following discharge have been
shown to result in dosage errors [28].
Frequent laboratory testing also represents a signifi-
cant burden and may be unrealistic for patients who
may be dependent on others for transportation and may
be challenged by physical limitations to mobility. These
impediments to frequent testing are especially relevant
for those patients who live in rural areas [29].
Pharmacist involvement in warfarin management
Literature from Australia [30-32] and overseas [33-35]
describes a role for pharmacists in anticoagulation man-
agement, particularly in the setting of anticoagulation
clinics. In the post-discharge setting, a randomised con-
trolled trial (RCT) of home visits and point-of-care
(POC) INR testing by a pharmacist improved the
initiation of warfarin therapy and resulted in a signifi-
cant decrease in haemorrhagic complications in the first
3 months of therapy [36]. One hundred and twenty
eight patients initiated on warfarin in hospital and sub-
sequently discharged to GP care in southern Tasmania
received 4 visits on alternate days, with the initial visit 2
days after discharge from hospital. At Day 8 post-dis-
charge, 67% of the intervention patients had a therapeu-
tic INR, compared with 42% of control patients (p <
0.005). Also, 26% of the control patients had a high
INR, compared with only 4% of intervention patients
[36].
Justification for this trial
While the previously described RCT was highly success-
ful, it involved only 1 dedicated pharmacist researcher
and a limited geographical area. In considering national
implementation of the service, the intensity of the 4-
visit model may not prove sustainable; thus, a trial
investigating 2-visit and 3-visit models is considered
necessary. It is also hoped that by integrating the war-
farin management service into the existing Home Medi-
cines Review (HMR) program, funded by the Australian
Government Department of Health and Ageing and
described below, sustainability of the service will be
assured.
Objectives
The objective of this trial is to develop and implement a
sustainable program to enable the smooth transition of
both newly anticoagulated patients and those already
taking warfarin from the hospital to community setting.
The aim is to assess whether pharmacist follow-up,
using 2 intensities of service across a diverse sample of
patients, leads to safer and more effective initiation of
anticoagulation, and is valued and welcomed by patients
and their GPs and community pharmacists.
Methods/Design
Overview
In summary, the post-discharge warfarin management
service consists of referral of patients discharged from
hospital taking warfarin to, and home follow-up by, a
pharmacist in the immediate post-discharge period. Sui-
table and consenting patients will receive either 2 or 3
home visits by an ‘accredited pharmacist’,a ne x p e r i -
enced, mobile pharmacy practitioner, within their first 8
to 10 days post-discharge. The visits will involve a HMR
to identify and resolve any post-discharge medication-
related issues, warfarin education and the provision of
resources depending on the patient’s understanding of
their warfarin therapy, and POC INR monitoring. The
study model is displayed in Figure 1.
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patients’ community pharmacy, with the results of the
INR monitoring and need for dose adjustment discussed
with the patients’ GPs. This complies with Australian
legislative requirements that preclude pharmacists from
independently recommending dose adjustments to
patients. After the post-discharge period, full care will
be returned to the patients’ community healthcare pro-
viders. The outcomes of patients receiving the service
will be compared with those receiving ‘usual care’;t h a t
PATIENT RECRUITMENT
Patient discharged from hospital on warfarin
Consent obtained from patient and GP
DAY 8
Assessment of INR control (POC INR monitoring), warfarin-
related adverse events, warfarin knowledge, QoL, adherence
DAY 90
Assessment of INR control (TTR), warfarin-related adverse 
events, warfarin knowledge, QoL, adherence 
USUAL CARE
Community-based healthcare providers resume full patient care 
INTERVENTION PHASE CONTROL 
PHASE
PATIENT/ GP 
REFUSAL
or patient otherwise 
inappropriate for 
service
USUAL CARE
HMR FACILITATION
GP forwards HMR referral to community 
pharmacy
Community pharmacist contacts trained 
accredited pharmacist and forwards on 
referral
POST-DISCHARGE HOME FOLLOW-
UP: 2 OR 3 VISITS (depending on risk
assessment)
Trained accredited pharmacist performs 
HMR, provides warfarin education and 
POC INR monitoring in liaison with GP 
(until 8-10 days post-discharge)
Figure 1 Study model.
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pathology providers, in a prospective, controlled cohort
study.
The HMR program and accredited pharmacists
As stated above, the study utilises the existing Austra-
lian HMR program, a program “designed to assist con-
sumers living at home to maximise the benefits of their
medication regimen and prevent medication-related pro-
blems” [37]. A HMR involves the patient, after referral
by their GP, being visited at home by an ‘accredited’
pharmacist who reviews their medication regimen, deli-
vers education and provides the GP with a report and
management suggestions. The GP and patient then
agree on a medication management plan. The process is
facilitated by the patient’s regular community pharma-
cist, which further assists in the development of coop-
erative working relationships between the members of
the patient’s healthcare team.
An ‘accredited’ pharmacist is “an experienced pharma-
cist who has undertaken specified education programs
or examinations, approved by the Australian Association
of Consultant Pharmacy (AACP) or the Society of Hos-
pital Pharmacists of Australia (SHPA)”,a sw e l la sc o m -
pleting continuing specified professional education and
regular reaccreditation [37].
Setting
The program will be implemented and trialled at 8 hos-
pital sites in the Australian states of New South Wales,
South Australia and Tasmania across a mix of Pharmacy
Access/Remoteness Index of Australia (PhARIA) classes.
The PhARIA classification provides a standardised mea-
surement of the physical and professional remoteness of
pharmacies throughout Australia [38]. It is a composite
index, incorporating measurements of general remote-
ness with a component of professional isolation repre-
sented by the road distance to the 5 closest pharmacies
[38]. The characteristics of the 8 hospitals are detailed
in Table 1.
Pre-implementation planning
Prior to trial implementation, project officers will be
recruited for each of the 8 study sites. Liaison will be
undertaken with key stakeholders at these sites to
ensure complete dissemination of study information.
Meetings and information evenings for GPs and phar-
macists will be organised and conducted at each site,
and details for email-outs, inclusions for newsletters and
on websites will be prepared.
Accredited pharmacist training
Accredited pharmacists interested in participating in the
study will be identified and required to complete the
“Anticoagulation Education Program for Accredited
Pharmacists”. This program, developed in collaboration
with consultant haematologists and general physicians,
is designed to provide the pharmacists with the addi-
tional training required to engage confidently in any dis-
cussions with GPs and other healthcare professionals
regarding warfarin dosing that may arise during their
involvement in the study. This program consists of 3
DVD-based modules of narrated Microsoft PowerPoint
®
presentations, with accompanying supporting material
on CD (slides of the presentations and copies of several
important references) and a comprehensive resource
manual. Participants will be allowed approximately 8
weeks to complete the 3 modules before attending a sin-
gle, 2-hour hands-on training session in their local area.
This session will offer the opportunity to practice INR
monitoring with a CoaguChek
® XS monitor (Roche
Diagnostics), and receive training in the study metho-
dology. Successful completion of the program will be
formally recognised by AACP as a contribution towards
each pharmacist’s mandatory annual continuing profes-
sional development requirements.
Assessment of participating pharmacists’ understand-
ing and ability to apply the program content will be
undertaken via a paper-based short answer assignment
on Modules 1 and 2, and an additional assignment of 5
warfarin dosing scenarios. Participants will be required
Table 1 Characteristics of the study sites
Study Site Location Number of beds (approx.) PhARIA Class
Royal Hobart Hospital Hobart, Tasmania 450 1
North West Regional Hospital Burnie, Tasmania 160 2
Royal North Shore Hospital St Leonards, New South Wales 600 1
Wollongong Hospital Wollongong, New South Wales 511 1
Concord Repatriation Hospital Concord, New South Wales 238 1
Royal Adelaide Hospital Adelaide, South Australia 650 1
Flinders Medical Centre Bedford Park, South Australia 516 1
Whyalla Hospital and Health Service Whyalla, South Australia 88 4
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their justification for their response; their responses will
be compared with the expert authors’ recommendations.
Quality control (QC) plan
The CoaguChek XS
® POC INR monitoring system will
be utilised during this study. The researchers have
extensive experience in the use of these monitors in
research and practice settings, and their accuracy and
ease of use have previously been proven in laboratory-
based performance verification studies [39], in the hands
of trained healthcare professionals in GP surgeries, com-
munity pharmacies and hospital outreach settings
[30,40], when used by trained patients undertaking
patient self-monitoring [41] and in special groups, such
as cancer patients [42].
While the internal quality control (IQC) systems in the
CoaguChek XS
® test strips ensure the precision of testing
[43], external QC (EQC) procedures are required to
ensure the accuracy of the results obtained. A QC plan
for the study has been devised in collaboration with con-
sultant haematologists and the Chief Hospital Scientist
from the Royal College of Pathologists of Australasia
(RCPA) Haematology Quality Assurance Program. The
QC plan is composed of 2 major components: accredited
pharmacist training (demonstrated competence in the
use of the CoaguChek
® XS INR monitor) and EQC.
Additionally, there are 2 facets to EQC:
1. Enrolment of the study monitors in the RCPA
Quality Assurance Program, where each monitor will be
subjected to testing at pre-specified times during the
course of the intervention; and
2. Comparison with laboratory INR results. Each
accredited pharmacist, a minimum of once during the
intervention phase, will be required to validate their
technique against a laboratory INR result by arranging
with a patient to perform a POC INR as close as possi-
ble to, but definitely within 4 hours of, a pathology INR
test. A deviation of the POC INR result of more than
15% from the laboratory result will result in the accre-
dited pharmacist being required to demonstrate their
INR monitoring technique to the project officer’ss a t i s -
faction, and re-testing of the monitor in question using
another monitor as the comparator, and its subsequent
removal from the study if a further significant deviation
is demonstrated. INR differences of up to 15% are con-
sidered acceptable for clinical purposes, and may also be
demonstrated between tests on the same sample in dif-
ferent pathology laboratories due to differences in the
collection and testing process [44].
Ethics approval
Ethics approval has been obtained from the Tasmanian
Health and Medical Human Research Ethics Committee
(Approval Number: H0010105); the Flinders Medical
Centre Clinical Research Ethics Committee (Clinical
Drug Trials Committee) (231/08); the Royal Adelaide
Hospital Research Ethics Committee (080910); the Uni-
versity of South Australia Human Research Ethics Com-
mittee (P252/08); and the Sydney South West Area
Health Service Human Research Ethics Committee at
Concord Repatriation General Hospital (HREC 08/
CRGH/206 CH62/6/2008-152). The study has been
registered on the Australia New Zealand Clinical Trials
Registry (ACTRN: 12608000334303).
Subjects
Hospitalised, adult patients initiated on warfarin during
admission or continuing pre-admission therapy are eligi-
ble for inclusion in the study. The inclusion and exclu-
sion criteria are detailed in Table 2.
Sample size
Based on sample size calculations, groups comprising
approximately 120 patients in each (control, 2-visit
model, and 3-visit model) are estimated as being statisti-
cally adequate. This is based on the previous RCT of
this model of care where 10% of the usual care group
experienced a major bleeding event within 90 days post-
discharge, which was reduced to 2% in the intervention
group [36]. Using these figures, approximately 108
patients are needed per group at a power of 80% and
p = 0.05. Published data are also available indicating
that approximately 30-40% of patients commenced
on warfarin experience a bleeding complication within
3 months [16,18,36,45]. The aim of the intervention pro-
gram is to reduce this figure to below 10%, in which
case approximately 72 patients are needed per group at
a power of 80% and p = 0.05. The proposed recruitment
targets are thus 160 in the control group and 240 in the
intervention group (120 receiving the 2-visit model and
120 the 3-visit model).
Patient recruitment
Potential patients will be identified via a variety of
mechanisms, including sourcing a daily list of INR
results from the hospitals’ pathology services; written or
verbal communication of the details of patients on war-
farin from pharmacy staff to project officers; and liaison
with nursing staff on key wards (e.g. coronary care
units, cardiothoracic surgery units) from where the
majority of patients are expected to be recruited.
Control patients
Potential control patients will be approached prior to
discharge and informed consent obtained for involve-
ment in the study using standard Information State-
ments and Consent Forms. Informed consent will also
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be collected during the patients’ admissions and imme-
diately after discharge.
After discharge from hospital, control patients will
receive ‘usual care’ according to their community health-
care provider’s usual practice. No restrictions will be based
on usual care, except that it cannot involve a formal post-
hospital outreach program as described in Table 2. Usual
care will thus typically involve the patient undergoing
venous blood sampling at their GP surgery or pathology
specimen collection centre and the result being reported
to the GP, who will then determine the need for dosage
adjustments and communicate them back to the patient
or carer. Alternative models of usual care may include the
patient undergoing POC testing in the GP surgery and
receiving immediate dosage adjustment advice during a
GP consultation or from the practice nurse, in liaison with
the GP; GPs or practice nurses utilising POC monitors
during home visits; or mobile phlebotomy services offering
venous sampling in the patient’s home, with subsequent
reporting of the result to the GP and communication of
dosing instructions to the patient or carer.
In the control phase of the study, a single home visit for
data collection purposes will be c o n d u c t e db yap r o j e c to f f i -
cer approximately 8 days post-discharge. At this visit, POC
INR monitoring will be performed and data will be col-
lected regarding the patients’ warfarin therapy and INR
results since discharge, medications and any adverse events.
Three questionnaires will be administered at this visit -
the EQ-5D quality of life (QoL) questionnaire, which has
been widely used across a number of clinical settings
[46,47]; a previously validated warfarin knowledge ques-
tionnaire, the Oral Anticoagulation Knowledge (OAK)
test [48]; and a modified Tool for Adherence Behaviour
Screening (TABS) survey [49]. While TABS was devel-
oped in patients with chronic obstructive pulmonary dis-
ease, it was designed as a non-specific tool to screen for
potential non-adherence in patients with chronic ailments
and possesses advantages over other commonly used
compliance measures in that it addresses both intentional
and unintentional non-adherence and over- and under-
utilisation.
A final follow-up will be conducted via telephone and
postal questionnaires (EQ-5D, the OAK test, TABS and
t h ed i s e a s e - s p e c i f i cD u k eA n t icoagulation Satisfaction
Scale (DASS)) [50] approximately 90 days post-discharge.
Corroboration of details of any adverse events experi-
enced by the patient and their current medications and
INR results will be requested from their GP at this time
via a postal form. Non-responders will receive a reminder
telephone call or fax after 4 to 8 weeks. For patients
experiencing readmission to hospital during their 90 days
post-discharge, Australian Refined Diagnosis Related
G r o u p( A R - D R G )c o d e sa n do t h e rd e t a i l sw i l lb e
obtained from their notes from the relevant hospital’s
Medical Records Department. The data to be collected at
each time point are summarised in Table 3.
Intervention patients
Following recruitment of a patient (as described for the
control patients above), the patient’sG Pw i l lb et e l e -
phoned by the project officer requesting verbal consent
for the patient’s participation in the study. Upon receipt
of verbal consent, a standard package will be faxed to
the GP surgery. This will contain an Information State-
ment and Consent Form, details of the patient’si n p a t i -
ent warfarin therapy to that time, and a HMR referral
form pre-populated by the project officer with informa-
tion gathered during the patient’s hospital admission to
expedite the referral process. The GP will be requested
to amend or complete any additional information on the
HMR referral form, sign and date it, and forward it to
the patient’s community pharmacy, who will subse-
quently engage an accredited pharmacist to provide the
service. This imitates the existing HMR referral process.
The community pharmacy will receive an identical faxed
copy of the patient’s warfarin therapy details and the
contact details of the trained accredited pharmacists in
the local geographical area to whom they can refer the
patient under the study protocol. Upon the patient’s
Table 2 Inclusion and exclusion criteria
Inclusion Criteria Exclusion Criteria
￿ hospital inpatients who were to be discharged on warfarin (newly
commenced or taking it upon hospital admission)
￿ patients suffering from lupus anticoagulant or antiphospholipid
syndrome
￿ indications for anticoagulation, including atrial fibrillation, venous
thromboembolism (deep vein thrombosis and/or pulmonary embolism)
and prosthetic valve replacement
￿ residents of aged care facilities and others not eligible for a HMR
￿ intended duration of anticoagulation of a minimum of 3 months ￿ patients with dementia, or otherwise unable to answer basic questions
about their therapy
￿ patients without a regular general practitioner and community
pharmacist through which an HMR could be arranged
￿ patients entering Hospital in the Home, Patients Acute Treatment and
Care in the Home, Acute/Post-Acute Care or similar outreach programs
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INR and warfarin dosing information and discharge
drug therapy via fax or email to the GP, community
pharmacist and accredited pharmacist.
After discharge from hospital, patients will receive
their follow-up home visits, based on a collaborative risk
assessment, approximately according to the study proto-
col detailed in Table 4.
Visit 1
Visit 1 will involve 4 components: the HMR, POC INR
monitoring, comprehensive warfarin education or rein-
forcement of previous education as required, and data
collection, including administration of the EQ-5D ques-
tionnaire and OAK test. Results of the POC INR moni-
toring will be communicated to the patient’sG Pf o r
dose adjustment if necessary. In the interests of patient
safety, an INR result above 3.5 will be designated as an
indication for immediate GP contact.
Based on an assessment of the patient’s bleeding risk,
the GP and accredited pharmacist will collaboratively
determine whether the patient will receive 1 (the ‘Level 1
Service’)o r2( t h e‘Level 2 Service’)s u b s e q u e n tv i s i t s .
This risk assessment will be based on calculation of their
Beyth Outpatient Bleeding Risk Index (which estimates a
patient’s risk of major bleeding within 3 and 12 months)
[51], INR stability and an overall evaluation encompass-
ing falls risk and drug interaction potential. A previously
utilised definition of stability will be utilised: “2 consecu-
tive INR results within the target range or the first mea-
surement in the therapeutic range when the previous or
subsequent INR varied by no more than 0.5 INR units
outside the target range” [52]. Only patients deemed to
be at ‘low’ or ‘intermediate’ risk based on the Beyth Out-
patient Bleeding Risk Index and with no other risk factors
will be candidates for the Level 1 Service. All other
patients - those at ‘high’ risk on the Beyth Outpatient
Bleeding Risk Index (due to their high estimated major
bleeding risk, or with additional risk factors, as detailed
above), will be mandated to receive the Level 2 Service.
Visits 2 and 3
Visits 2 and 3 will provide opportunities for POC INR
monitoring, provision of warfarin education and resolu-
tion of any detected drug-related problems. If patients
require more frequent INR tests than the service can
offer, pathology testing in combination with POC INR
testing will be permitted.
Table 3 Data collection summary
Data Time point
Baseline Visit
1
Visit
2*
Visit 3
i or
Day 8
c
Day
90
Demographics, alcohol intake, smoking history, drug history, height, weight, serum creatinine,
haematocrit
✓
Warfarin therapy details- indication, intended duration, target INR, newly commenced or continuing,
heparin pre-treatment, inpatient doses/INRs, doses/INR on discharge, warfarin counselling documented
✓
Medications, warfarin drug interactions ✓✓ ✓
Medical history ✓
INR ✓✓ ** ✓** ✓** ✓
Warfarin dosing/INR history ✓✓ ✓
Number of GP consultations (since discharge, or between Days 8 and 90) ✓✓
Adverse events, hospital readmissions ✓✓
Warfarin continuing, reason for discontinuation ✓✓ ✓ ✓
Beyth Bleeding Risk score ✓
C ✓
I
Warfarin dose, changes recommended, visit outcome, visit length, travel time ✓✓ ✓
QoL (EQ-5D), warfarin knowledge ✓✓ ✓
QoL (Duke Anticoagulation Satisfaction Scale (DASS)) ✓
Adherence (Tool for Adherence Behaviour Screening (TABS)) ✓✓
Self-reported health services utilisation ✓
(* Visit 2 if required, ** POC monitoring,
C Control,
I Intervention).
Table 4 Timing of post-discharge visits under the 2 levels
of service
Level of Service Number of Days Post-Discharge
Visit 1 Visit 2* Visit 3
’Level 1 Service’ (2-visit model) 2-3 days - 7-8 days
’Level 2 Service’ (3-visit model) 2-3 days 4-6 days 8-10 days
(* All patients will receive the visits designated as Visit 1 and 3; Visit 2 is the
optional additional visit).
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collected, the TABS survey administered and the EQ-5D
questionnaire and OAK test re-administered. The accre-
d i t e dp h a r m a c i s tw i l lf o r w a r dac o p yo ft h e i rH M R
report and the standard handover document to the
patient’s GP and community pharmacy. A similar hand-
over document will be given to the patient.
Day 90 follow-up will be conducted for these patients
as described for the control phase. In addition, stake-
holders immediately involved with this service (patients,
GPs, community and accredited pharmacists) will be
surveyed to assess their satisfaction with the service and
identify its perceived advantages, deficiencies and sug-
gested improvements to the process to inform its future
evolution and implementation. A structured postal ques-
t i o n n a i r ew i l lb ei n c l u d e dw i t ht h eD a y9 0d a t ac o l l e c -
tion forms for intervention patients to complete
regarding their experience. The GPs, community phar-
macists and accredited pharmacists will be surveyed at
the completion of the recruitment period.
Outcome measures
The primary outcome measure will be the proportion of
patients experiencing a major bleeding event in the 90
days after hospital discharge. Major bleeding will be
defined using the previously accepted definition of:
“fatal bleeding, and/or symptomatic bleeding in a
critical area or organ (especially intracranial or ret-
roperitoneal), and/or bleeding causing a fall in hae-
moglobin level of 2 g/dL or more, or leading to
transfusion of two or more units of whole blood or
red cells” [53].
Secondary outcome measures will be the combined
incidence of major bleeding and thromboembolic events,
death, cessation of warfarin therapy, INR control at 8
days post-discharge and unplanned hospital readmis-
sions from any cause. INR control will be calculated
based on the patient’s individual target INR range, and
d e f i n e da ss u c ha sw i t h i nt h i sr a n g e( ’therapeutic’),
below the range (’subtherapeutic’)o ra b o v et h er a n g e
(’supratherapeutic’) .R a t e so fI N R sg r e a t e rt h a n4w i l l
also be investigated as this confers a markedly increased
risk of intracranial haemorrhage [54].
Other outcomes will include INR control to Day 90,
QoL, warfarin knowledge, other adverse events (includ-
ing minor bleeding) and adherence. Minor bleeding will
be defined as bleeding requiring health professional con-
sultation, but not hospitalisation, to ensure consistency
and minimise the risk of recall bias. The EQ-5D utility
score for QoL will be calculated using the United King-
dom Time Trade-Off data set, as has been reported pre-
viously [47]. No Australasian data set is currently
available. Time in therapeutic INR range will be calcu-
lated using Rosendaal’s linear interpolation method [55].
Warfarin drug interaction severity ratings will be classi-
fied as ‘Severe’, ‘Moderate’, ‘Caution’, ‘Minor’ and ‘Nil’
using the eMIMS database [56], while medical history
will be based on the International Classification of Dis-
eases 10 coding system (ICD-10) [57].
Statistical analysis
Demographic data will be utilised to compare the con-
trol and intervention groups for a range of parameters
(e.g. age, gender, PhARIA class, living and medication
management arrangements, co-morbidities, warfarin
drug interactions) using independent samples t-testing
for continuous data and chi-squared analysis for catego-
rical data. Outcome data will be reported using para-
metric statistics, with independent samples t-testing
utilised for the majority of continuous variables and chi-
squared analysis for the majority of discrete variables.
Data will be statistically analysed across the 3 groups
(control, Level 1 Service, and Level 2 Service). For the
evaluation questionnaires, responses will be recorded on
modified Likert scales, with 0 representing “Strongly
agree” and 10 “Strongly disagree”. Qualitative feedback
will obtained via open-ended questions. Data analysis
will involve descriptive statistics and thematic analysis of
the qualitative responses.
Discussion
The post-discharge period is well recognised as a
high-risk time for patients taking warfarin [16,17,
19-22,58,59]. POC INR testing has been suggested to
have a number of advantages, including availability of
the INR level at the same time as the consultation with
a healthcare professional, improved compliance with
warfarin as a result of the face-to-face interaction,
increased convenience for the patient, more appropriate
use of warfarin in rural and remote areas, and overcom-
ing difficulties of frequent venepuncture [60]. There is
also a strong focus on warfarin education as part of this
intervention as studies have generally shown an inverse
relationship between patient knowledge and adverse
outcomes of warfarin therapy [61]. Patients’ knowledge,
drug compliance and anticoagulant control all improve
after patient education becomes part of a structured
management program [61-64].
The prospective, controlled cohort study design has
been chosen in preference to a RCT as the focus of the
program is on translation of the previous successful
research program into practice, rather than solely
demonstrating the benefits of the service. It is also
believed that there is the strong possibility of a marked
Hawthorne effect if the control and intervention phases
were to occur simultaneously in the same hospital
Stafford et al. BMC Health Services Research 2011, 11:16
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standard practice and a potential detriment to patient
care. A multi-centred cluster RCT would require many
more hospitals, time and expense, and would be likely
to lead to difficulties in attracting collaborating hospitals
and participants. Additionally, it was deemed impossible
to blind participants to which phase of the trial in
which they were involved.
The trial faces several potential challenges, including
the necessity for an expedited GP consent/HMR referral
process to ensure that the first home visit occurs within
2 to 3 days post-discharge. Previous work in this area at
the Royal Adelaide Hospital has achieved post-discharge
HMRs within 6.5 days post-discharge, varying from 3.9
to 8.1 days depending on slight variations in the model
[65]. The time to the conduct of a post-discharge HMR
can be as long as 18 [66] or 32 days [67]. The timeliness
of the HMR is particularly important, not only because
of the requirement for INR monitoring, but also because
post-discharge medication reviews are best conducted
soon after discharge (some authors recommend within 1
week) [65] to best enable opportunities to enhance med-
ication adherence, improve medication related knowl-
edge and identify medication-related problems (as the
probability of medication misadventure is recognised as
being highest during the 10 day post-discharge period)
[68]. As discussed, processes have been implemented to
address this and other potential challenges as completely
as possible during the study planning stage using learn-
ings from the previous trial. The study’s other strengths
lie in a strong multidisciplinary team and the use of an
existing referral and funding structure.
Based on the excellent results of the previously trialled
program [36], this service has been proposed as a poten-
tial solution to many of the issues faced in the post-dis-
charge period by patients taking warfarin. The aim is to
incorporate POC INR monitoring and warfarin educa-
tion into the existing HMR remuneration structure to
produce a streamlined and sustainable model more
pragmatic for widespread implementation into practice.
It is hoped that this study will provide the evidence to
support the national roll-out of the program as a new
professional community pharmacy service.
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